VASO Corp
No SEC Form 4 filings for $VASO in the last 30 days.
See all $VASO insider activity →Vaso Corporation's stock surged 149% in the past year, outperforming industry peers and the S&P 500. The company reported higher revenues and profitability in Q2 2026, driven by growth in professional sales services and equipment segments. Recent developments include the sale of NetWolves and a focus on healthcare businesses. Vaso's valuation remains below industry average but above its historical median.
VASO Corp (VASO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01. Entry into a Material Definitive Agreement. On July 31, 2026, Vaso Corporation (“Vaso”), VasoTechnology, Inc., a Delaware corporation and wholly owned subsidiary of Vaso (“VasoTech”), NetWolves Network Services LLC, a Florida limited liability company and wholly owned
VASO Corp (VASO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000839087 0000839087 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VASO (VASO Corp). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VASO coverage spans financial news, mergers & acquisitions and corporate actions.
Momentum appears supported by improving fundamentals and a simplified portfolio, but the stock’s outlook remains sensitive to GE HealthCare delivery continuity and VasoMedical margin pressure.
Deal closing is a concrete corporate event that can change VASO’s asset base, cash flows, and risk profile, but the excerpt lacks deal size and financial impact.
Board and audit-committee composition changes may modestly affect governance and oversight expectations, but no operational or financial guidance is provided.
VASO reported record revenue in Q1 2025 with a narrowed net loss, yet the stock declined post-earnings. This suggests investor caution or profit-taking despite solid financial performance.
AlphAI scores every news story that mentions VASO with an AI model for sentiment and relevance, and aggregates insider trades from VASO Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Vaso Corporation's stock surged 149% in the past year, outperforming industry peers and the S&P 500. The company reported higher revenues and profitability in Q2 2026, driven by growth in professional sales services and equipment segments. Recent developments include the sale of NetWolves and a focus on healthcare businesses. Vaso's valuation remains below industry average but above its historical median.
7 min readVASO Corp (VASO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01. Entry into a Material Definitive Agreement. On July 31, 2026, Vaso Corporation (“Vaso”), VasoTechnology, Inc., a Delaware corporation and wholly owned subsidiary of Vaso (“VasoTech”), NetWolves Network Services LLC, a Florida limited liability company and wholly owned
6 min readVASO Corp (VASO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000839087 0000839087 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
2 min readVASO's first-quarter 2025 revenues hit a record high, but a narrowed net loss and muted stock reaction highlight investor caution despite solid segment growth.
3 min read
